Major Depressive Disorder News and Research

RSS

Major Depressive Disorder (MDD) is a psychiatric condition characterized by depressed mood or anhedonia (significant loss of interest or pleasure). The condition affects more than 15.7 million adults and approximately 3 million adolescents (aged 13 to 17 years) in the USA each year.

New clinical uses for old hypertension drug leads to several patents

University of South Florida neuroscientist R. Douglas Shytle's discovery of successful new clinical uses for mecamylamine, a drug once used to treat hypertension, has led to several issued patents on mecamylamine and related compounds. Earlier this month, Shytle, associate professor and research scientist at the USF Center of Excellence for Aging and Brain Repair and the USF Silver Child Development Center, received the university's 2009 "Excellence in Innovation" award.

28 Oct 2009

New therapy for decreasing anxiety and improving psychological well-being in children

A group of investigators of the University of Bologna suggest a new way of approaching emotional disturbances in children by improving their psychological well-being. The study is published in the current issue of Psychotherapy and Psychosomatics.

27 Oct 2009

Study explores the link between child sexual abuse and inability to express emotions in adulthood

An investigation published in the current issue of Psychotherapy and Psychosomatics explores the link between child sexual abuse and inability to express emotions in adulthood.

27 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

The Patient Recruiting Agency begins patient recruitment for major depressive disorder

The Patient Recruiting AgencyTM announces that on October 20th 2009 it will begin recruiting patients with major depressive disorder for a series of medical research studies.

21 Oct 2009

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in CNS and oncology, today announced top-line results from a Phase IIa clinical study of Serdaxin™, its major depressive disorder (MDD) drug candidate.

20 Oct 2009

Novel HIV drug to be studied in cell cultures and patients

A $6 million, five-year federal grant to The Children's Hospital of Philadelphia Research Institute will enable researchers to investigate a novel approach in treating HIV infection---a unique class of drugs focused on developing therapies for psychological and neurological effects in AIDS.

19 Oct 2009

9% of Québec adults report being diagnosed with a thyroid disease

New research reveals 9 percent of Québec adults report being diagnosed with a thyroid disease. The thyroid gland produces the hormones that regulate our growth, maturation, speed of metabolism and sensitivity to other hormones.

13 Oct 2009

Web-based TV program to focus on holistic lifestyle

The outcome of the current healthcare legislation is uncertain, but one matter is clear: Americans need to get healthier. From childhood obesity to alarming rates of clinical depression among adults, people across the U.S. have been confronted with the consequences of lives off-balance.

9 Oct 2009

Awards dedicated to those working to fight against depression

The Welcome Back Awards is now accepting nominations to honor those who work in the depression community. The Welcome Back Awards is a program established by Eli Lilly and Company to recognize outstanding achievements in the fight against depression and the stigma often associated with the illness.

25 Sep 2009

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

The Weill Cornell Institute of Geriatric Psychiatry at NewYork-Presbyterian Hospital/Westchester Division announced today it has received the largest grant in its 20-year history. One of a handful awarded nationally, the new $10 million, five-year "Center Grant" from the National Institute of Mental Health (NIMH) will enable NewYork-Presbyterian/Weill Cornell investigators to advance their pioneering work in understanding the biological, medical, cognitive and psychosocial problems of depressed seniors.

25 Sep 2009

Bioscience Research offers mental health care at no cost

Psychiatrists at Bioscience Research, LLC, understand the mental health burden that can accompany unemployment and the day-to-day stress of looking for a new job or worrying about losing an existing job.

22 Sep 2009

Health of American workers trending downwards

In the midst of the most vigorous national health care debate in 15 years, and at a time of heightened economic insecurity, new data on employers show that the health of employed American workers is trending downward in a number of important areas. The State of Health in the American Workforce, a report released today by the Families and Work Institute (FWI), finds that only 28% of employees today report that their overall health is "excellent," down from 34% just six years ago.

22 Sep 2009

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Aspect Medical Systems, Inc. (NASDAQ: ASPM) today announced that two companion articles highlighting results from the BRITE-MD (Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major Depression) were published in the September issue of the journal Psychiatry Research.

11 Sep 2009

Biomarkers for rapid identification of treatment effectiveness in major depression

Now, based on the final results of a nationwide study led by UCLA, clinicians may be able to accurately predict within a week whether a particular drug will be effective by using a non-invasive test that takes less than 15 minutes to administer. The test will allow physicians to quickly switch patients to a more effective treatment, if necessary.

11 Sep 2009

Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics, today confirmed plans to present data from its completed Phase 2b clinical trial of TC-5214 as an augmentation treatment for major depressive disorder at the Nicotinic Acetylcholine Receptors as Therapeutic Targets Symposium (nAChR2009) in Lincolnshire, Illinois on October 15, 2009.

10 Sep 2009

Half of six million major depressive disorder with comorbid panic attack cases go untreated

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that in the U.S., out of six million cases of major depressive disorder with comorbid panic attack, three million are untreated. Comorbid mental disorders are influential factors impacting the diagnosis and treatment of mental disorders.

10 Sep 2009

Labopharm to present its novel trazodone formulation data

Labopharm Inc. today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation.

10 Sep 2009

Research study examines the depression rate in chronic kidney disease patients

One in five patients with chronic kidney disease is depressed, even before beginning long-term dialysis therapy or developing end-stage renal disease, UT Southwestern Medical Center researchers have found.

9 Sep 2009

Major Depressive Disorder News and Research

Further Reading

New clinical uses for old hypertension drug leads to several patents

New therapy for decreasing anxiety and improving psychological well-being in children

Study explores the link between child sexual abuse and inability to express emotions in adulthood

Schering-Plough announces 2009 third quarter financial results

The Patient Recruiting Agency begins patient recruitment for major depressive disorder

Targacept presents data from Phase 2b clinical trial of TC-5214

Rexahn Pharmaceuticals announces positive results from Phase IIa Serdaxin clinical study

Novel HIV drug to be studied in cell cultures and patients

9% of Québec adults report being diagnosed with a thyroid disease

Web-based TV program to focus on holistic lifestyle

Awards dedicated to those working to fight against depression

$10 million grant to Weill Cornell Institute from NIMH to study geriatric depression

Bioscience Research offers mental health care at no cost

Health of American workers trending downwards

Results from the BRITE-MD trials published in Psychiatry Research: Aspect Medical Systems

Biomarkers for rapid identification of treatment effectiveness in major depression

Phase 2b clinical trial results of TC-5214 to be presented at nAChR2009

Half of six million major depressive disorder with comorbid panic attack cases go untreated

Labopharm to present its novel trazodone formulation data

Research study examines the depression rate in chronic kidney disease patients

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News